Apyx Medical (APYX) vs Lucid Diagnostics (LUCD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Apyx Medical (APYX) has outperformed Lucid Diagnostics (LUCD) over the past year, losing 40.0% versus a loss of 64.7%. Over five years, APYX leads with a -83.4% price change compared with -95.6% for LUCD. Apyx Medical is the larger company by market cap ($101.1 million vs $72.6 million), about 1.4 times the size.
Apyx Medical converts more of its revenue into profit, with a net margin of -21.2% versus -1232.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APYX | LUCD |
|---|---|---|
| Share price | $2.40 | $0.3727 |
| Market cap | $101.10M | $72.57M |
| 1-day change | +0.42% | -3.52% |
| YTD return | -31.43% | -65.81% |
| 1-year return | -40.00% | -64.67% |
| 5-year return | -83.40% | -95.58% |
| EPS (TTM) | $-0.19 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $52.84M | $4.71M |
| Revenue growth (YoY) | +9.86% | +8.28% |
| Net income (latest FY) | $-11.21M | $-58.01M |
| Gross margin | 62.53% | -41.73% |
| Operating margin | -12.20% | -1054.82% |
| Net margin | -21.22% | -1232.68% |
| 52-week high | $5.08 | $1.63 |
| 52-week low | $2.25 | $0.303 |
| Distance from 52-week high | -52.76% | -77.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +170.83% | +973.25% |
| Average volume | 146.81K | 5.15M |
| Shares outstanding | 42.12M | 194.71M |
| Employees | 205 | 82 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- APYX has outperformed LUCD by 24.7 percentage points over the past year.
- Apyx Medical is more profitable, keeping -21.2 cents of every revenue dollar as net income versus -1232.7 cents for Lucid Diagnostics.
About Apyx Medical
APYX stock →Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM).
Health Care · Medical/Dental Instruments · 205 employees
About Lucid Diagnostics
LUCD stock →Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
Health Care · Medical/Dental Instruments · 82 employees
APYX vs LUCD FAQ
Which is bigger, Apyx Medical or Lucid Diagnostics?
Apyx Medical (APYX) is larger, with a market capitalization of $101.10M compared with $72.57M for Lucid Diagnostics (LUCD).
Which stock has performed better over the past year, APYX or LUCD?
APYX returned -40.00% over the past 12 months, compared with -64.67% for LUCD (price return, excluding dividends). Past performance does not predict future results.
Are Apyx Medical and Lucid Diagnostics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.